Your day-by-day guide to ASCO

30 May - 2 June 2009

Orange County Convention Center
Orlando, FL, USA
<table>
<thead>
<tr>
<th>Section</th>
<th>Page</th>
</tr>
</thead>
<tbody>
<tr>
<td>Congress details</td>
<td>2</td>
</tr>
<tr>
<td>Dining</td>
<td>3</td>
</tr>
<tr>
<td>Safety</td>
<td>5</td>
</tr>
<tr>
<td>Congress site plan</td>
<td>6</td>
</tr>
<tr>
<td>Investigator Meetings</td>
<td>8</td>
</tr>
<tr>
<td>Key</td>
<td>9</td>
</tr>
<tr>
<td>Saturday 30 May</td>
<td>10</td>
</tr>
<tr>
<td>Sunday 31 May</td>
<td>13</td>
</tr>
<tr>
<td>Monday 1 June</td>
<td>16</td>
</tr>
<tr>
<td>Hotels</td>
<td>19</td>
</tr>
<tr>
<td>Map</td>
<td>20</td>
</tr>
</tbody>
</table>
Congress details

Congress venue
Orange County Convention Center
9800 International Drive
Orlando, FL 32819, USA
Tel: 407 885 98 00  Fax: 407 885 98 84

Congress registration
Location: West Hall C, Orange County Convention Center
Friday 29 May: Onsite registration opens
(including self-registration)
Tuesday 2 June: Onsite registration closes

Congress dates and opening hours
Friday 29 May       13:00-18:00
Saturday 30 May     08:00-18:00
Sunday 31 June      08:00-18:00
Monday 1 June       08:00-18:00
Tuesday 2 June      08:00-13:00

Exhibit opening hours
Saturday 30 May - Monday 1 June       08:00-17:00
Congress site plan

Roche Investigator Meeting shuttle bus
(between West Concourse Building and Rosen Centre)

West Building

Exhibition Halls

Meeting Rooms / Chapin Theater

Chapin Theater Balcony Level and Valencia

LEVEL IV

LEVEL III

LEVEL II

LEVEL I

PARKING

Exhibition Halls / Meeting Rooms

Ramp to Level II
Key to symbols used throughout the planner

<table>
<thead>
<tr>
<th>Symbol</th>
<th>Drug</th>
</tr>
</thead>
<tbody>
<tr>
<td>A</td>
<td>Avastin</td>
</tr>
<tr>
<td>H</td>
<td>Herceptin</td>
</tr>
<tr>
<td>M</td>
<td>MabThera</td>
</tr>
<tr>
<td>P</td>
<td>Pertuzumab</td>
</tr>
<tr>
<td>P</td>
<td>PLX4032 (R7204)</td>
</tr>
<tr>
<td>T</td>
<td>Tarceva</td>
</tr>
<tr>
<td>T</td>
<td>T-DM1</td>
</tr>
<tr>
<td>X</td>
<td>Xeloda</td>
</tr>
</tbody>
</table>
**POSTER DISPLAY/DISCUSSION SESSION**

**Time:** 08:00-13:00 [discussion 12:00-13:00]
**Venue:** Level 2, W240A [Level 2, West Hall E1]

**Breast Cancer – Metastatic**

**A** A phase II study of trastuzumab-DM1 (T-DM1), a HER-2 antibody-drug conjugate (ADC), in patients (pts) with HER-2+ metastatic breast cancer (MBC): Final results (CL Vogel; Poster 9, Abstract 1017)

**P** Pertuzumab monotherapy following trastuzumab-based treatment: Activity and tolerability in patients with advanced HER-2-positive breast cancer (J Cortès; Poster 14, Abstract 1022)

**A** Tolerability and efficacy of first-line bevacizumab (B) plus chemotherapy (CT) in elderly patients with advanced breast cancer (aBC): Sub-population analysis of the MO19391 study (L Biganzoli; Poster 24, Abstract 1032)

**A** Safety and efficacy of first-line bevacizumab (B) plus chemotherapy (CT) for locally recurrent or metastatic breast cancer (LR/mBC): Analysis of MO19391 according to CT (J Pierga; Poster 25, Abstract 1033)

**ORAL ABSTRACT SESSION**

**Time:** 13:00-16:00
**Venue:** Level 2, West Hall F1

**Lymphoma**

**M** Benefit of rituximab combined to ACVBP (R-ACVBP) over ACVBP in 209 poor risk BDLC NHL patients treated with up-front consolidative autotransplantation: A GELA phase 2 trial (LNH 2003–3) (N Mounier; Abstract 8507)

**Time:** 13:15-13:30

**Time:** 14:00-14:15
R-ICE versus R-DHAP in relapsed patients with CD20 diffuse large B-cell lymphoma (DLBCL) followed by autologous stem cell transplantation: CORAL study (C Gisselbrecht; Abstract 8509)
Time: 14:00-14:15

Long-term follow-up of patients with follicular lymphoma (FL) receiving single agent rituximab at two different schedules in study SAKK 35/98 (ME Ghielmini; Abstract 8512)
Time: 15:00-15:15

GENERAL POSTER SESSION

Time: 14:00-18:00
Venue: Level 2, West Hall C

Lung Cancer – Metastatic

Preliminary safety and effectiveness of bevacizumab (BV) based treatment in subpopulations of patients (pts) with non-small cell lung cancer (NSCLC) from the ARIES study: A bevacizumab (BV) treatment observational cohort study (OCS) (NA Fischbach; Poster M21, Abstract 8040)

MO19390 (SAiL): Safety and efficacy of first-line bevacizumab (Bv)-based therapy in advanced non-small cell lung cancer (NSCLC) (L Crino; Poster N3, Abstract 8043)

Efficacy and safety of first-line bevacizumab (Bv) and cisplatin/gemcitabine (CG) in elderly patients (pts) with advanced non-small cell lung cancer (NSCLC) in the BO17704 study (AVAiL) (NB Leighl; Poster N12, Abstract 8050)
ORAL ABSTRACT SESSION

Time: 15:00-18:00
Venue: Level 3, W330A

Central Nervous System Tumors

Safety of bevacizumab in patients with metastases to the central nervous system (UP Rohr; Abstract 2007)
Time: 17:15-17:30
GENERAL POSTER SESSION

Time: 08:00-12:00
Venue: Level 2, West Hall C

Gastrointestinal (Colorectal) Cancer

- mFOLFOX-bevacizumab or XELOX-bevacizumab then bevacizumab (B) alone or with erlotinib (E) in first-line treatment of patients with metastatic colorectal cancer (mCRC): Interim safety analysis of DREAM study (C Tournigand; Poster G18, Abstract 4077)

- Efficacy and safety of bevacizumab (BEV)-based combination regimens in patients with metastatic colorectal cancer (mCRC): Randomized phase II study of BEV + FOLFIRI versus BEV + XELIRI (FNCLCC ACCORD 13/0503 study) (M Ducreux; Poster H11, Abstract 4086)

Gastrointestinal (Noncolorectal) Cancer

- Pathological features of advanced gastric cancer (GC): Relationship to human epidermal growth factor receptor 2 (HER2) positivity in the global screening programme of the ToGA trial (Y Bang; Poster N6, Abstract 4556)

POSTER DISPLAY/DISCUSSION SESSION

Time: 08:00-12:00 [discussion 11:00-12:00]
Venue: Level 3, W340A [Level 2, West Hall E2]

Lung Cancer – Metastatic

- Biomarker analyses from the phase III placebo-controlled SATURN study of maintenance erlotinib following first-line chemotherapy for advanced NSCLC (W Brugger; Poster 12, Abstract 8020)
SUNDAY
31 MAY

POSTER DISPLAY/DISCUSSION SESSION

Time: 08:00-12:30 [discussion 11:30-12:30]
Venue: Level 3, W340A [Level 2, West Hall F3]

Melanoma

PLX4032, a highly selective V600EBRAF kinase inhibitor: Clinical correlation of activity with pharmacokinetic and pharmacodynamic parameters in a phase I trial (I Puzanov; Poster 9, Abstract 9021)

ORAL ABSTRACT SESSION

Time: 09:00-12:00
Venue: Level 2, West Hall E1

Lung Cancer – Metastatic

SATURN: A double-blind, randomized, phase III study of maintenance erlotinib versus placebo following nonprogression with first-line platinum-based chemotherapy in patients with advanced NSCLC (F Cappuzzo; Abstract 8001)
Time: 09:15-09:30

A randomized, double blind, placebo controlled, phase IIIb trial (ATLAS) comparing bevacizumab (B) therapy with or without erlotinib (E) after completion of chemotherapy with B for 1st-line treatment of locally-advanced, recurrent, or metastatic non-small cell lung cancer (NSCLC) (VA Miller; Abstract LBA8002)
Time: 09:30-09:45
PLENARY SESSION

Time: 13:00-16:00
Venue: Level 2, West Hall D2

General Oncology, Special & Plenary Sessions

A phase III trial comparing mFolfox to mFolfox6 + bevacizumab in stage II or III carcinoma of the colon: Results of NSAPB Protocol C-08 (N Wolmark; Abstract LBA4)
Time: 15:15-15:30

POSTER DISPLAY/DISCUSSION SESSION

Time: 14:00-18:00 [discussion 17:00-18:00]
Venue: Level 2, W230A [Level 2, West Hall D1]

Gastrointestinal (Noncolorectal) Cancer

Rash as a marker for the efficacy of gemcitabine plus erlotinib-based therapy in pancreatic cancer: Results from the AViTA Study (C Verslype; Poster 21, Abstract 4532)
Monday
1 June

POSTER DISPLAY/DISCUSSION SESSION
Time: 08:00-12:00 [discussion 11:00-12:00]
Venue: Level 2, W240A [Level 2, West Hall E1]

Gastrointestinal (Colorectal) Cancer
International randomized phase III study of capecitabine (Cap), bevacizumab (Bev), and mitomycin C (MMC) in first-line metastatic colorectal cancer (mCRC): Final results of the AGITG MAX trial (NC Tebbutt; Poster 14, Abstract 4023)

ORAL ABSTRACT SESSION
Time: 09:30-12:15
Venue: Level 2, West Hall D1

Genitourinary (Testes, Kidney, and Bladder) Cancer
Bevacizumab plus interferon-alpha versus interferon-alpha monotherapy in patients with metastatic renal cell carcinoma: Results of overall survival for CALGB 90206 (BI Rini; Abstract LBA5019)
Time: 11:15-11:30

Final results of the phase III, randomized, double-blind AVOREN trial of first-line bevacizumab (BEV) + interferon-α2a (IFN) in metastatic renal cell carcinoma (mRCC) (BJ Escudier; Abstract 5020)
Time: 11:30-11:45

ORAL ABSTRACT SESSION
Time: 09:30-12:30
Venue: Level 2, West Hall D2

Breast Cancer – Metastatic
Quantitative assessment of HER-2 status and correlation with efficacy for patients (pts) with metastatic breast cancer (MBC) in a phase II study of trastuzumab-DM1 (T-DM1) (IE Krop; Abstract 1003)
Time: 10:30-10:45
RIBBON-1: Randomized, double-blind, placebo-controlled, phase III trial of chemotherapy with or without bevacizumab (B) for first-line treatment of HER2-negative locally recurrent or metastatic breast cancer (MBC) (NJ Robert; Abstract 1005)
Time: 11:15-11:30

**GENERAL POSTER SESSION**

*Time: 13:00-17:00*
*Venue: Level 2, West Hall C*

**Breast Cancer – Local-Regional and Adjuvant Therapy**

Assessment of trastuzumab-related cardiac dysfunction in the Herceptin Adjuvant (HERA) trial with 3.6 years median follow-up (MJ Procter; Poster A6, Abstract 540)

Clinical benefit of bevacizumab (BV) plus first-line docetaxel (D) in elderly patients (pts) with locally recurrent (LR) or metastatic breast cancer (mBC): AVADO study (X Pivot; Poster M7, Abstract 1094)

**Breast Cancer – Metastatic**

The effect of age on overall survival (OS) in patients with metastatic breast cancer (MBC) treated with capecitabine (JL Blum; Poster M12, Abstract 1097)

**ORAL ABSTRACT SESSION**

*Time: 15:00-17:45*
*Venue: Level 2, West Hall D1*

**Gastrointestinal (Noncolorectal) Cancer**

Efficacy results from the ToGA trial: a Phase III study of trastuzumab added to standard chemotherapy (CT) in first-line human epidermal growth factor receptor 2 (HER2)-positive advanced gastric cancer (GC) (E van Cutsem; Abstract LBA4509)
Time: 15:00-15:15
Monday

1 June

CLINICAL SCIENCE SYMPOSIUM

Time: 16:30-18:00
Venue: Level 4, Valencia Room, W415A

Molecular Phenotype of Melanoma Subtypes and Patient-Specific Therapy

Phase I study of PLX4032: Proof of concept for V600E BRAF mutation as a therapeutic target in human cancer (K Flaherty; Abstract 9000)
Time: 16:30-16:45
Hotels

Buena Vista Palace
1900 Buena Vista Drive
32830 Orlando, FL
Tel: 407 827 27 27
www.buenavistapalace.com
Breakfast: Great Hall Assembly Area, 07:00-11:30

Caribe Royale
8101 World Center Drive
32821 Orlando, FL
Tel: 407 238 80 00
www.cariberoyale.com
Breakfast: The Tropical Restaurant, 06:30-11:30

Courtyard by Marriott
8623 Wineland Avenue
32821 Orlando, FL
Tel: 407 938 90 01
www.marriott.com
Breakfast: Courtyard Café, Mon-Fri 06:30-09:30,
Sat-Sun 07:00-10:00

Wyndham
8001 International Drive
32819 Orlando, FL
Tel: 407 351 24 20
www.wyndham.com
Breakfast: Lemon, Lime and Tangerine room, 06:30-09:30
Map